[Clinical and cardiohemodynamic effects of the new long-acting beta-blocker tobanum].
The effects of long-acting beta-adrenoblocker tobanum on the frequency and severity of anginal attacks, bicycle ergometry, echocardiographic parameters of intracardiac hemodynamics, pulse rate, arterial blood pressure were studied in comparison with the respective effects of the short-acting beta-adrenoblocker anaprilin and the long-acting beta-blocker corgard in 45 coronary patients with stable angina of functional classes I through IV. Tobanum produced antianginal effect in 82.2% of cases, and was well tolerated. The effect of one 5 mg pill set on later, as compared to anaprilin, and lasted longer (averaging 12 hours).
L I
LI
Ol'binskaia
O A
OA
Vartanova
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D003327:Coronary Disease / Q000150:complications; D005260:Female; D006321:Heart / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D009248:Nadolol; D011433:Propranolol; C025725:tobanum
Klinicheskie i kardiogemodinamicheskie éffekty novogo prolongirovannogo beta-adrenoblokatora tobanuma.